Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients

Inclusion Criteria: * Recipient of a primary or secondary deceased or living (related or not) donor kidney transplant and who requires basiliximab induction therapy. * Cold ischemia time \< 30 hours. * Women of child-bearing age, even those with a history of infertility, must have had a negative pregnancy test during the 7 days before screening or at the time of screening, and must use a recognized and reliable method of contraception throughout the study and for 2 months after discontinuing the study treatment. * Patients who want and are able to take part in the entire study, and have given their written consent. * Patients who are registered with a French national health insurance scheme or are covered by such a scheme. Exclusion Criteria: * Recipient of multi-organ transplantation, including dual kidneys, or who have previously received non renal transplant organ. * Patients receiving a graft from a non-heart-beating donor. * Anti-HLA antibody levels ≥ 20% in the last 3 months before the inclusion. * ABO incompatible graft or with positive cross match T. * Severe hyperlipidemia: total cholesterol ≥ 9.1 mmol/L (≥ 350 mg/dL) and/or triglycerides ≥ 8.5 mmol/L (≥ 750 mg/dL) despite appropriate lipid-lowering therapy. * Known hypersensitivity or contraindications to mycophenolic acid, cyclosporine or lactose. * Known hypersensitivity or contraindications to macrolides or drugs of the mTOR inhibitor class. * HIV seropositive, or active chronic hepatitis B (HBs Ab) or C. Resu…